LMU Department of Cardiology LMU Heart Valve Center
  • EuroSMR Risk Score
  • EuroSMR Publications
      HFrEF SMR Stages
        RV Dysfunction
          COAPT criteria
            GDMT
              Proportionality
                Gender
                  LA Volume
                    Residual MR
                      Antroprometics
                        AFMR
                          EROA
                        • EuroSMR Centers
                        1. EuroSMR
                        2. EuroSMR Publications
                        3. Gender

                        Gender

                        Sex-Related Clinical Characteristics and Outcomes of Patients Undergoing Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation

                        JACC: Cardiovascular Interventions, 2021, doi: 10.1016/j.jcin.2020.12.042

                        Objectives: The authors sought to assess sex-based differences in characteristics and outcomes of patients undergoing transcatheter edge-to-edge mitral valve repair (TMVR) for secondary mitral regurgitation (SMR).

                        Background: Subgroup analysis from the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial indicated potential sex-related differences in outcomes after TMVR. The impact of sex on results after TMVR in a real-world setting is unknown.

                        Methods: The authors assessed clinical outcomes and echocardiographic parameters in women and men undergoing TMVR for SMR between 2008 and 2018 who were included in the large, international, multicenter real-world EuroSMR registry (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation).

                        Results: A total of 1,233 patients, including 445 women (36%) and 788 men (64%), were analyzed. Although women were significantly older and had fewer comorbidities than men, TMVR was equally effective in women and men (mitral regurgitation [MR] grade ≤2+ at discharge: 93.2% vs. 94.6% for women vs. men; p = 0.35). All-cause mortality at 1 year (17.9% vs. 18.9%, adjusted hazard ratio: 0.806; p = 0.46) and at 2-year follow-up (26.5% vs. 26.4%, adjusted hazard ratio: 0.757; p = 0.26) were similar in women versus men after multivariate regression analysis. Durability of MR reduction, improvement in symptoms, quality of life, and functional capacity did also not differ during follow-up.

                        Conclusions: Results from the EuroSMR registry confirmed effective and similar MR reduction with TMVR in women and men. There were no sex-related differences in clinical outcomes up to 2 years of follow-up.

                        Under the lead of the EuroSMR Center LMU Munich.

                        Park SD, Orban M, Karam N, Lubos E, Kalbacher D, Braun D, Stolz L, Neuss M, Butter C, Praz F, Kassar M, Petrescu A, Pfister R, Iliadis C, Unterhuber M, Lurz P, Thiele H, Baldus S, von Bardeleben S, Blankenberg S, Massberg S, Windecker S, Hausleiter J

                        Login for editors
                        Imprint | Data-Safety
                      • LMU Department of Cardiology
                      • LMU Heart Valve Center
                      • EuroSMR

                        • EuroSMR Risk Score
                        • EuroSMR Publications
                          • HFrEF SMR Stages
                          • RV Dysfunction
                          • COAPT criteria
                          • GDMT
                          • Proportionality
                          • Gender
                          • LA Volume
                          • Residual MR
                          • Antroprometics
                          • AFMR
                          • EROA
                        • EuroSMR Centers